CAMP and glioblastoma: Based on these findings, we hypothesized that activation of systemic anti‐tumor immune response by CAMP‐activated NE treatment could improve immunosuppressive environment, which concomitantly would synergize with ICI such as aPD‐1, resulting in a positive therapeutic outcome in case of GBM.